About Diagnostear
Diagnostear is a company based in Tel Aviv (Israel) founded in 2013.. Diagnostear has raised $2.85 million across 2 funding rounds from investors including Elcam Medical. Diagnostear offers products and services including TeaRx Dry Eye, TeaRx Red Eye, and TeaRx Tear Collector. Diagnostear operates in a competitive market with competitors including Pr3vent, Toku Eyes, TearLab, Gobiquity and Quantel Medical, among others.
- Headquarter Tel Aviv, Israel
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Diagnostear Technologies, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$2.85 M (USD)
in 2 rounds
-
Latest Funding Round
$2.85 M (USD), Series A
Oct 19, 2020
- Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Diagnostear
Diagnostear is a publicly listed company on the CSE with ticker symbol DTR in Canada, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Diagnostear
Diagnostear offers a comprehensive portfolio of products and services, including TeaRx Dry Eye, TeaRx Red Eye, and TeaRx Tear Collector. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Test for identifying and monitoring Dry Eye Syndrome.
Assesses conditions like adenoviral conjunctivitis and allergic conjunctivitis.
Microfluidic device for collecting tear fluid samples.
Funding Insights of Diagnostear
Diagnostear has successfully raised a total of $2.85M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $2.85 million completed in October 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series A — $2.9M
- First Round First Round
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2020 | Amount | Series A - Diagnostear | Valuation | Elcam Medical |
|
| Oct, 2015 | Amount | Series A - Diagnostear | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Diagnostear
Diagnostear has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Elcam Medical. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Diagnostear
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Diagnostear
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Diagnostear Comparisons
Competitors of Diagnostear
Diagnostear operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Pr3vent, Toku Eyes, TearLab, Gobiquity and Quantel Medical, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
AI-based platform for newborn ophthalmic condition screening is offered.
|
|
| domain | founded_year | HQ Location |
AI-powered retinal images are analyzed for early disease detection.
|
|
| domain | founded_year | HQ Location |
Developer of diagnostic tests for detecting hyperosmolarity
|
|
| domain | founded_year | HQ Location |
Smartphone apps are developed to detect and track eye diseases.
|
|
| domain | founded_year | HQ Location |
Ultrasound and laser devices for ophthalmology are manufactured and marketed.
|
|
| domain | founded_year | HQ Location |
Provider of diagnostic, screening, and lens finishing equipment for eye care
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Diagnostear
Frequently Asked Questions about Diagnostear
When was Diagnostear founded?
Diagnostear was founded in 2013 and raised its 1st funding round 2 years after it was founded.
Where is Diagnostear located?
Diagnostear is headquartered in Tel Aviv, Israel.
Is Diagnostear a funded company?
Diagnostear is a funded company, having raised a total of $2.85M across 2 funding rounds to date.
What does Diagnostear do?
Diagnostear is focussed on developing a point of care diagnostic test for dry eye syndrome (DES). It has developed an assay test called TeaRx based on various reagents that create color reactions when comes in contact with tear film and then provides a multi-parameter semi-quantitative analysis to identify the underlying causes of DES. As of October 2016, the test is in clinical development has shown positive second clinical study results in January 2016. The company DiagnosTear is part of BioLights XLVision Sciences ophthalmology cluster.
Who are the top competitors of Diagnostear?
What products or services does Diagnostear offer?
Diagnostear offers TeaRx Dry Eye, TeaRx Red Eye, and TeaRx Tear Collector.
Is Diagnostear publicly traded?
Yes, Diagnostear is publicly traded on CSE under the ticker symbol DTR.
Who are Diagnostear's investors?
Diagnostear has 1 investor. Key investors include Elcam Medical.
What is Diagnostear's ticker symbol?
The ticker symbol of Diagnostear is DTR on CSE.